A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.
This week, I had a chance to sit down with Food and Drug Administration Commissioner Dr. Marty Makary during a trip to Washington, D.C.
Our conversation came in the midst of a contentious stretch for the FDA, defined by a leadership transition, massive staff and budget cuts and sweeping changes to vaccine policy and the agency’s drug approval approach. Most recently, its back-and-forth on Moderna’s flu shot has fueled industry concern about regulatory consistency.
Here’s what Makary had to say on some of the topics top of mind for the pharmaceutical industry.
Watch my interview with Makary here.
